Meropenem Inresa

Meropenem, the active ingredient in Meropenem Inresa, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It treats severe bacterial infections such as intra‑abdominal infections, urinary tract infections, pneumonia, septicemia and meningitis in hospitalized patients. GNH USA supplies Meropenem Inresa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections in the hospital setting. - Complicated intra‑abdominal infections: provides bacterial eradication in severe abdominal sepsis. - Complicated urinary tract infections: eliminates resistant uropathogens causing kidney and bladder infections. - Nosocomial pneumonia: treats hospital‑acquired lung infections resistant to other antibiotics. - Septicemia: rapidly clears bloodstream infections caused by Gram‑negative and Gram‑positive bacteria. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: may be watery and self‑limiting. - Rash: skin redness or itching. - Headache: transient headache during treatment. - Elevated liver enzymes: mild, reversible increase in transaminases. - Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Anaphylaxis: acute allergic reaction with respiratory and circulatory compromise. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Neutropenia: marked reduction in white blood cells. - Acute renal failure: worsening kidney function in susceptible individuals.

Use meropenem with careful clinical monitoring and consider patient‑specific factors. - Renal function: adjust dose in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other beta‑lactams. - Pregnancy: prescribe only if the potential benefit justifies the potential risk to the fetus. - Valproic acid co‑administration: monitor for reduced valproate levels and possible seizure breakthrough. - Seizure risk: observe patients with a history of CNS disorders for neurologic signs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Valproic acid: meropenem reduces plasma valproate concentrations, increasing seizure risk. - Probenecid: may decrease renal clearance of meropenem, leading to higher systemic exposure.

Moderate Interactions (Monitor Closely): - Loop diuretics: combined use may heighten nephrotoxicity. - Aminoglycosides: additive risk of kidney injury when given together. - Warfarin: monitor INR as meropenem can alter anticoagulant effect. - CNS stimulants (e.g., caffeine, theophylline): may lower seizure threshold.